ACTRN12620000184976撤回1 期
A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of Two Dosage Forms of BTX 1702 in Patients with Papulopustular Rosacea
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Patient has a diagnosis at Screening and Baseline of papulopustular rosacea of the face defined as:
- •a.15 to 75 (inclusive) inflammatory lesions (papules/pustules) on the face;
- •b.An Investigator’s Global Assessment (IGA) score for rosacea severity of 3 or 4 (moderate or severe), assessed on the face.
- •c.Clinician’s Erythema Assessment (CEA) score of 3 or 4 (moderate or severe) assessed on the face.
- •d.Absence of comedones.
- •e.Independent reviewer confirmation of rosacea patients with erythema and papules/pustules of the face.
- •2. Patient has <2 nodular lesions (>5 mm in diameter).
- •3. Absence or presence of telangiectasia.
- •4. Patient agrees to not use marijuana or cannabidiol (CBD) products throughout the study.
- •5. A negative urine pregnancy test result for all women of child-bearing potential at the Screening Visit and Baseline Visit.
- •6. Sexually active women must agree to use contraception throughout the study and for 30 days after last study drug application.
- •7. Male patients must refrain from sperm donation during the course of the study and until 90 days post study drug administration.
排除标准
- •1. Patient with a history of known or suspected intolerance to the drug product excipients (hexamethyldisiloxane, dimethicone, polypropylene glycol (PPG) 15 stearyl ether) and Silicone Gum 1515.
- •2. Patient has used any marijuana products, via any route, within 4 weeks prior to the Screening Visit. A positive urine drug screen for tetrahydrocannabinol (THC) will exclude the patient.
- •3. Patient has any significant active infection.
- •4. Patient has known human immunodeficiency viruses (HIV) infection or hepatitis B or C.
- •5. Patient has initiated a hormonal method contraception within 3 months of Baseline or plans to discontinue during the course of the study, or changed product within 3 months of Baseline or plans to change during the course of the study.
- •6. Patient has used topical acne or rosacea treatments within 4 weeks of Baseline.
- •7. Patient has used systemic retinoids within 90 days of Baseline.
- •8. Patient has used topical or systemic antibiotics within 4 weeks of Baseline.
- •9. Patient is using or plans to use a clinically significant concomitant/prohibited drug therapy, treatment or procedure..
- •10. Patient has used (>14 days) topical or systemic anti-inflammatories in the 4 weeks prior to Baseline.
- •11. Patient has used topical or systemic corticosteroids 4 weeks prior to Baseline.
- •12. Patient has used vasodilating agents (eg. anti-hypertensives, erectile dysfunction drugs, nitroglycerin) 6 weeks prior to Baseline.
- •13. Patient has used alpha-adrenergic receptor-blocking agents 6 weeks or alpha-adrenergic agonists 4 weeks prior to Baseline.
- •14. Patient has ocular rosacea and/or blepharitis/meibomianitis and require treatment by an ophthalmologist during the course of the study.
- •15. Patient has sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality that would result in the inability to perform study assessments.
- •16. Patient has an active or potentially recurring skin conditions(s) other than rosacea that will interfere with the assessment of rosacea.
- •17. Patient has clinically significant or severe allergies that in the investigator’s opinion would interfere with participation in the study.
- •18. Patient has used systemic or other immunosuppressive medications within 4 weeks of the Baseline Visit (inhaled corticosteroid less than or equal to 1000 µg daily dose is acceptable).
- •19. Patient has used phototherapy 14 days prior to Baseline or has had excessive sun exposure with intent to sunbathe or tan or use artificial tanning agents.
- •20. Patient has other dermatological conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments such as, but not limited to, acne or atopic dermatitis.
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82